[Pharmacologic treatment of acute migraine attack in children].
Migraine, according to the criteria of the International Headache Society, occurs in about 5 to 10% of children. Management of acute headache is only one of the parts of the treatment, along with identification of migraine precipitants, adjustments in lifestyle, and when necessary the use of preventive therapy, which can include non pharmacologic (relaxation or biofeedback) or pharmacologic treatment. In the acute migraine attack, a single dose of either ibuprofen 10 mg/kg or paracetamol 15 mg/kg has been shown to be effective, with only a few adverse effects. In severe migraine attacks, dihydroergotamine mesylate administered orally (20 to 40 microg/kg) or intravenously (maximum 1 mg/day) may be helpful, but there have been no large placebo-controlled trials of this treatment. Among the different triptans, it is the sumatriptan nasal spray whose efficacy has been best demonstrated. The most frequent adverse event is transitory unpleasant taste.
Cuvellier
J C
JC
Service de neuropédiatrie, clinique de pédiatrie, hôpital Roger-Salengro, centre hospitalier régional et universitaire de Lille, 59037 Lille cedex, France. jc-cuvellier@chru-lille.fr
Joriot
S
S
Auvin
S
S
Vallée
L
L
D000082:Acetaminophen / Q000008:administration & dosage / Q000627:therapeutic use; D000208:Acute Disease; D000281:Administration, Intranasal; D000284:Administration, Oral; D000293:Adolescent; D000367:Age Factors; D018712:Analgesics, Non-Narcotic / Q000008:administration & dosage / Q000627:therapeutic use; D001676:Biofeedback, Psychology; D002648:Child; D004087:Dihydroergotamine / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007052:Ibuprofen / Q000008:administration & dosage / Q000627:therapeutic use; D007275:Injections, Intravenous; D008019:Life Style; D008881:Migraine Disorders / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D012064:Relaxation Therapy; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000627:therapeutic use; D018170:Sumatriptan / Q000008:administration & dosage / Q000627:therapeutic use; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000627:therapeutic use
D018712:Analgesics, Non-Narcotic; D017366:Serotonin Receptor Agonists; D014662:Vasoconstrictor Agents; D000082:Acetaminophen; D004087:Dihydroergotamine; D018170:Sumatriptan; D007052:Ibuprofen